Presentation is loading. Please wait.

Presentation is loading. Please wait.

STATUS ASTHMATICUS Sigrid Hahn, MD Andy Jagoda, MD, FACEP Department of Emergency Medicine Mount Sinai School of Medicine New York, New York.

Similar presentations


Presentation on theme: "STATUS ASTHMATICUS Sigrid Hahn, MD Andy Jagoda, MD, FACEP Department of Emergency Medicine Mount Sinai School of Medicine New York, New York."— Presentation transcript:

1 STATUS ASTHMATICUS Sigrid Hahn, MD Andy Jagoda, MD, FACEP Department of Emergency Medicine Mount Sinai School of Medicine New York, New York

2 Status Asthmaticus: A Case Study  35 year old male with a week of progressive difficulty breathing  Using albuterol inhaler every hour, ran out several days prior to presentation  Multiple hospitalizations with two intubations  PMH: none  Meds: albuterol inhaler  Smokes “a few cigarettes” per day

3 Status Asthmaticus: A Case Study  BP 150/90, P 120, RR 28; pulse oximetry 92%  Alert, speaking in clipped sentences; sitting upright and appearing very anxious  Lungs: severe inspiratory and expiratory wheezing, minimal air movement  Heart: tachycardic  CXR hyperinflation, no pneumothorax

4 Indicators of Severe Asthma  Anxious & diaphoretic appearance, upright position  Breathlessness at rest and inability to speak in full sentences  PaCO 2 normal or increased  PEFR < 150 L/min or <50% predicted  Pulse oximetry < 91% on room air  Tachycardia (HR>120) and tachypnea (RR>30) Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. National Institute of Health- National Heart, Lung and Blood Institute 1997; NIH publication number

5 Approach to Severe Asthma  Reverse bronchoconstriction  Treat airway inflammation  Correct hypoxemia  Consider differential diagnosis  Monitor for complications  Pneumothorax  Hypotension

6 In the management of a severe asthma exacerbation…  How should beta-agonists be administered?  Do anti-cholinergics have a role?  Does aminophylline have a role?  Does magnesium have a role?  Should heliox be used?  Does ketamine have a role?  Should non-invasive ventilation be used?  What should the ventilator settings be if the patient is intubated?

7 How should beta-agonists be administered?   Inhaled  -agonists are the treatment of choice   In a small trial, there was no significant difference in response to delivery by nebulization, MDIs with spacers, or inhaled powder Raimondi AC et al. Chest 1997 Jul; 112:24-28  The optimal dose of inhaled  -agonists varies among patients; dose should be titrated to effect  Continuous treatments have been shown to be safe in patients with underlying cardiac disease Olshaker et al. Am J Emerg Med 1993;11:131 Olshaker et al. Am J Emerg Med 1993;11:131

8 If the patient is unable to tolerate inhaled  -agonists …  SC  -agonists are an alternative to inhaled  -agonists  A randomized trial compared SC epinephrine mg with SC terbutaline mg  Patients years old  Similar increases in PEFR and FEV at 5 and 15 minutes  No difference in heart rate or blood pressure  Continuous ECG revealed no dysrhythmias Spiteri: Subcutaneous adrenaline versus terbutaline in the treatment of acute severe asthma. Thorax 1988; 43:19-23

9 Should IV  -agonist therapy be used?   Meta-analysis evaluated 9 RCTs comparing IV  - agonists in addition to, or instead of, inhaled  -agonists in severe asthma in adults   No significant differences were found in multiple outcome measures between the two groups   If the patient can tolerate inhaled  -agonists, there is no evidence to support the use of IV  -agonists Travers et al. The Cochrane Library, Issue 3,   Small trial found a benefit of IV  -agonists in children Browne et al. Lancet 1997; 349:

10 All patients with a severe asthma exacerbation should receive steroids  60 – 125 mg IV methylprednisolone  mg PO prednisone

11 Should anticholinergics be used in addition to  -agonists?   Multiple doses of inhaled ipratropium bromide in addition to  -agonists lead to a significant improvement in pulmonary function tests   Benefits most pronounced in those with FEV 1<30% Rodrigo. The Role of Anticholinergics in Acute Asthma Treatment- An Evidence-Based evaluation. Chest 2002;

12 Is there a role for IV aminophylline?  Multiple theoretically beneficial effects  Cochrane review included 15 trials and found no benefit over  -agonists alone in PFTs or admission rates, even in severe asthma  Increase in adverse effects (palpitations, vomiting) Parameswaran et al. The Cochrane Library, Issue 3, 2003  No studies compare outcome in patients with severe asthma who are unable to tolerate inhaled  -agonists  There is no evidence supporting its use

13 Is there a role for IV magnesium?  Smooth muscle relaxation (bronchodilation)   2 gm of MgSO4 is safe and beneficial in patients with severe acute asthma exacerbations (FEV1<25% predicted) Rowe. Magnesium sulfate for treating exacerbations of acute asthma in the emergency room (Cochrane Review) The Cochrane Library. Issue 3, 2003.

14 What is heliox?  Helium/Oxygen mixture  Laminar flow reduces the resistance associated turbulent airflow in more proximal airways  Allows greater oxygen delivery during inspiration  Reduced work of breathing

15 Should heliox be used in severe asthma?  Review found no improvement in PFTs regardless of heliox mixture or severity of disease  Heliox-driven nebulizers were associated with a non-significant improvement in PFTs at one hour Rodrigo. Chest 2003; 123: Rodrigo. The Cochrane Library. Issue 3, 2003

16 Does IV ketamine improve outcome?  Ketamine is a bronchodilator, potentiates catecholamines  44 consecutive patients with severe asthma attacks received IV ketamine (0.1 mg/kg bolus and 0.5 mg/kg/hour infusion) for 3 hours  Ketamine was used in conjunction with other standard therapies  No difference in PEFR or hospital admission Howton. Randomized, double-blind, placebo-controlled trial of IV ketamine in acute asthma. Annals of Emergency Medicine. 27(2)

17 Does noninvasive ventilation improve outcome?   BiPAP can reduce work of breathing, reduce bronchoconstriction and offset intrinsic PEEP   Small trial used BiPAP in 30 patients with severe asthma after one neb in the ED   Excluded patients with hypotension, Osat < 90%, depressed mental status, need for emergent intubation   BiPAP was interrupted for short periods to deliver nebulized albuterol   Significant improvement in PFTs Soroksky et al. A Pilot Prospective, RCT of BiPAP in Acute Asthma Attack. Chest :

18 Who should be intubated?  Decision should be based on clinical deterioration (altered mental status, respiratory fatigue)  Neither hypoxia nor hypercarbia are absolute indications for intubation

19 Rapid Sequence Intubation in the Asthmatic  Oxygenate  Premedicate  Lidocaine  Glycopyrollate or atropine  Induction with ketamine  Paralysis with succinylcholine  Intubation with large ETT

20 Mechanical Ventilation in Asthma  Volume cycled ventilation  FiO  Rate 8-10  I:E 1:4 or 1:5  V T 5-7 cc/kg  PEEP 0  Maintain peak pressures < 45 cm H 2 0, plateau pressure < 30 cm H20

21 If peak pressures remain > 45 mm Hg…  Evaluate for pneumothorax  Ensure sedation & paralysis  Allow hypercapnea (up to 80 mmHg)  Consider pressure-controlled ventilation

22 Complications of Mechanical Ventilation  Hypotension  Barotrauma

23 CONCLUSIONS  Beta-agonists are first line therapy  Aminophylline does not have a role in the management of acute asthma  Anticholinergics and magnesium may improve PFTs in severe asthma  Consider using noninvasive ventilation  Intubation is based on clinical status, not on numbers  Ventilator management is based on permissive hypercapnea


Download ppt "STATUS ASTHMATICUS Sigrid Hahn, MD Andy Jagoda, MD, FACEP Department of Emergency Medicine Mount Sinai School of Medicine New York, New York."

Similar presentations


Ads by Google